Literature DB >> 16116331

The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice.

Virginia S Lemos1, Denise M R Silva, Thomas Walther, Natalia Alenina, Michael Bader, Robson A S Santos.   

Abstract

Recently, we demonstrated that the endothelium-dependent vasodilator effect of angiotensin(1-7) in the mouse aorta is abolished by genetic deletion of the G protein-coupled receptor encoded by the Mas protooncogene. To circumvent the limitations posed by the possible metabolism of Ang(1-7) in this vessel, in this work we studied the mechanism underlying the vasorelaxant effect of AVE 0991, a nonpeptide mimic of the effects of Ang(1-7), using wild-type and Mas-deficient mice. Ang(1-7) and AVE 0991 induced an equipotent concentration-dependent vasodilator effect in aortic rings from wild-type mice that was dependent on the presence of endothelium. The vasodilator effect of Ang(1-7) and AVE 0991 was completely blocked by 2 specific Ang(1-7) receptor antagonists, A-779 and D-Pro-Ang(1-7), and by inhibition of NO synthase with L-NAME. Moreover, in aortic rings from Mas-deficient mice, the vasodilator effect of both Ang(1-7) and AVE 0991 was abolished. In contrast, the vasodilator effect of acetylcholine and substance P were preserved in Mas-null mice. In addition, the vasoconstriction effect induced by Ang II was slightly increased, and the vasodilation induced by the AT2 agonist CGP 42112A was not altered in Mas-deficient mice. Our results show that Ang(1-7) and AVE 0991 produced an NO-dependent vasodilator effect in the mouse aorta that is mediated by the G protein-coupled receptor Mas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116331     DOI: 10.1097/01.fjc.0000175237.41573.63

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  30 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

2.  Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2.

Authors:  Vaibhav B Patel; Abhijit Takawale; Tharmarajan Ramprasath; Subhash K Das; Ratnadeep Basu; Maria B Grant; David A Hall; Zamaneh Kassiri; Gavin Y Oudit
Journal:  J Mol Med (Berl)       Date:  2015-04-15       Impact factor: 4.599

Review 3.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

Review 4.  Macrophages in neuroinflammation: role of the renin-angiotensin-system.

Authors:  Anna Hammer; Johannes Stegbauer; Ralf A Linker
Journal:  Pflugers Arch       Date:  2017-02-11       Impact factor: 3.657

5.  Cerebral and skeletal muscle feed artery vasoconstrictor responses in a mouse model with greater large elastic artery stiffness.

Authors:  Ashley E Walker; Elise K Kronquist; Kerrick T Chinen; Kelly D Reihl; Dean Y Li; Lisa A Lesniewski; Anthony J Donato
Journal:  Exp Physiol       Date:  2019-02-03       Impact factor: 2.969

Review 6.  Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke.

Authors:  Douglas M Bennion; Emily Haltigan; Robert W Regenhardt; U Muscha Steckelings; Colin Sumners
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

7.  Differential effects of Mas receptor deficiency on cardiac function and blood pressure in obese male and female mice.

Authors:  Yu Wang; Robin Shoemaker; David Powell; Wen Su; Sean Thatcher; Lisa Cassis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-16       Impact factor: 4.733

8.  Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas.

Authors:  Concepción Peiró; Susana Vallejo; Florian Gembardt; Erika Palacios; Susana Novella; Verónica Azcutia; Leocadio Rodríguez-Mañas; Carlos Hermenegildo; Carlos F Sánchez-Ferrer; Thomas Walther
Journal:  J Physiol       Date:  2013-03-04       Impact factor: 5.182

9.  Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

Authors:  Chandana B Herath; Josephine A Grace; Peter W Angus
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

Review 10.  Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension.

Authors:  Rodrigo Araujo Fraga-Silva; Anderson Jose Ferreira; Robson Augusto Souza Dos Santos
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.